company background image
CLVS.Q logo

Clovis Oncology OTCPK:CLVS.Q Voorraadrapport

Laatste prijs

US$0.015

Marktkapitalisatie

US$2.2m

7D

18.1%

1Y

-99.4%

Bijgewerkt

12 Jul, 2023

Gegevens

Financiële gegevens bedrijf

Clovis Oncology, Inc.

OTCPK:CLVS.Q Voorraadrapport

Marktkapitalisatie: US$2.2m

CLVS.Q Overzicht aandelen

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally.

CLVS.Q fundamentele analyse
Sneeuwvlok Score
Waardering2/6
Toekomstige groei0/6
Prestaties in het verleden0/6
Financiële gezondheid0/6
Dividenden0/6

Clovis Oncology, Inc. Concurrenten

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Clovis Oncology
Historische aandelenkoersen
Huidige aandelenkoersUS$0.015
52 Week HoogtepuntUS$2.87
52 Week LaagUS$0.01
Bèta0.66
11 maand verandering-40.00%
3 maanden verandering-28.57%
1 Jaar Verandering-99.39%
33 jaar verandering-99.77%
5 jaar verandering-99.97%
Verandering sinds IPO-99.88%

Recent nieuws en updates

Recent updates

Clovis Oncology rises on clinical supply agreement with Isotopia

Sep 21

Clovis stock rises 15% as Rubraca shows survival benefit as maintenance therapy for ovarian cancer in trial

Sep 12

Clovis Oncology: Needs Some Encouraging Data Quickly

Aug 11

These Analysts Think Clovis Oncology, Inc.'s (NASDAQ:CLVS) Sales Are Under Threat

Aug 10
These Analysts Think Clovis Oncology, Inc.'s (NASDAQ:CLVS) Sales Are Under Threat

Clovis Oncology Q2 2022 Earnings Preview

Aug 05

EMA recommends restricted use of Clovis cancer drug

Jul 22

Clovis Oncology climbs 34% as shareholders reject reverse stock split

Jul 08

Clovis: Shifting Toward Nuclear Medicine

Apr 25

Clovis Oncology: Forging A Fresh Perspective

Mar 31

News Flash: 4 Analysts Think Clovis Oncology, Inc. (NASDAQ:CLVS) Earnings Are Under Threat

Feb 24
News Flash: 4 Analysts Think Clovis Oncology, Inc. (NASDAQ:CLVS) Earnings Are Under Threat

Buying Beaten Down Clovis Oncology Stock Ahead Of 2022 Catalysts

Jan 11

Clovis Oncology Is Now Discounted And Offers A Great Risk-Reward

Dec 30

Clovis Oncology Stock: Only Glimmers Of Hope

Oct 07

Clovis: Compelling With Upcoming Catalysts

Jul 30

Here's Why Shareholders May Want To Be Cautious With Increasing Clovis Oncology, Inc.'s (NASDAQ:CLVS) CEO Pay Packet

Jun 17
Here's Why Shareholders May Want To Be Cautious With Increasing Clovis Oncology, Inc.'s (NASDAQ:CLVS) CEO Pay Packet

Clovis Oncology and Inovio gain amid Reddit chatter

Jun 09

Clovis Oncology: Another Upcycle Coming

May 08

Clovis Oncology drops 7% as Rubraca sales missed estimates amid continued COVID-19 headwinds

May 05

Don't Ignore The Fact That This Insider Just Sold Some Shares In Clovis Oncology, Inc. (NASDAQ:CLVS)

Mar 17
Don't Ignore The Fact That This Insider Just Sold Some Shares In Clovis Oncology, Inc. (NASDAQ:CLVS)

How Much Did Clovis Oncology's(NASDAQ:CLVS) Shareholders Earn From Share Price Movements Over The Last Three Years?

Feb 22
How Much Did Clovis Oncology's(NASDAQ:CLVS) Shareholders Earn From Share Price Movements Over The Last Three Years?

Clovis Oncology: Recent Rally Already Has Me Changing My Game Plan

Jan 31

Clovis Oncology: Finally Green Shoots May Be On The Horizon

Jan 29

Clovis Oncology reports preliminary Q4 Rubraca revenue between $43.0M to $43.5M

Jan 11

What Kind Of Investors Own Most Of Clovis Oncology, Inc. (NASDAQ:CLVS)?

Dec 31
What Kind Of Investors Own Most Of Clovis Oncology, Inc. (NASDAQ:CLVS)?

Clovis Oncology submits FAP-2286 applications for therapeutic and imaging clinical trial

Dec 29

Clovis stock rises as rubraca shows survival benefit in late-stage ovarian cancer study

Dec 21

Clovis Oncology existing holder purchases additional $7.5M convertible senior notes

Nov 25

Clovis Oncology: Cash Position Is Tight, We Question Management's Guidance

Nov 09

Clovis Oncology: Reloading Before And After Q3 Earnings For The Long Term

Nov 06

Clovis Oncology EPS beats by $0.11, misses on revenue

Nov 05

Rendement voor aandeelhouders

CLVS.QUS BiotechsUS Markt
7D18.1%-1.3%-1.6%
1Y-99.4%19.1%30.1%

Rendement versus industrie: CLVS.Q presteerde slechter dan de US Biotechs -sector, die het afgelopen jaar een rendement van 19.1 % opleverde.

Rendement versus markt: CLVS.Q presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 30.1 % opleverde.

Prijsvolatiliteit

Is CLVS.Q's price volatile compared to industry and market?
CLVS.Q volatility
CLVS.Q Average Weekly Movement61.3%
Biotechs Industry Average Movement9.6%
Market Average Movement6.1%
10% most volatile stocks in US Market15.1%
10% least volatile stocks in US Market3.0%

Stabiele aandelenkoers: De aandelenkoers van CLVS.Q is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van CLVS.Q is het afgelopen jaar gestegen van 39% naar 61%.

Over het bedrijf

OpgerichtWerknemersCEOWebsite
2009413Patrick Mahaffywww.clovisoncology.com

Clovis Oncology, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Clovis Oncology zich tot de beurswaarde?
CLVS.Q fundamentele statistieken
MarktkapitalisatieUS$2.18m
Inkomsten(TTM)-US$251.91m
Inkomsten(TTM)US$133.02m

0.0x

P/S-verhouding

0.0x

Koers/Winstverhouding

Is CLVS.Q overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
CLVS.Q resultatenrekening (TTM)
InkomstenUS$133.02m
Kosten van inkomstenUS$31.59m
BrutowinstUS$101.43m
Overige uitgavenUS$353.33m
Inkomsten-US$251.91m

Laatst gerapporteerde inkomsten

Sep 30, 2022

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)-1.73
Brutomarge76.25%
Nettowinstmarge-189.37%
Schuld/Eigen Vermogen Verhouding-158.0%

Hoe presteerde CLVS.Q op de lange termijn?

Bekijk historische prestaties en vergelijking